• $234k EBITDA for Q2, up 92% vs Q1
• Record quarterly sales revenue of $4.61m, up 41% vs PCP
• Gross margin maintained above 60% for Q2

Biome Australia Limited (ASX: BIO) is pleased to provide its Appendix 4C and Activity Report for the quarter ended 31 December 2024. The company reported positive EBITDA of $234k for Q2, an increase of 92% compared to Q1 ($122k). Quarterly sales revenue reached a new record of $4.61m, which was $101k ahead of the Q2 forecast and represents a 41% increase compared to the previous corresponding period (PCP) (Q2 FY24). Cash receipts increased to $4.34m, up 41% vs PCP, and gross margin was maintained above 60%. Biome has achieved positive EBITDA over four consecutive quarters and expects to report its first net profit in the audited half-year accounts for H1, FY25. The company received $15k from the exercise of options in Q2, and cash flow from operating activities for Q2 was a net inflow of $107k. During the quarter, Biome completed the transfer payment for its novel probiotic strain, Lactobacillus Plantarum BMB18, which has been lodged with the German culture bank DSMZ.

Biome expects to report its first net profit for H1 FY25.

Biome's Vision 27 strategic plan is well on track, and the company is carefully managing opex and measured investments to drive strong growth in both sales revenue and EBITDA.